Evidence map›Paper›PMID 29671157›Full record

ReviewDigestive diseases and sciences2018

Natural History of the Post-ablation Esophagus.

Craig C Reed, Nicholas J Shaheen

Registry-linked trialAbstract readReview
PubMed Publisher
In one paragraph

Review in Digestive diseases and sciences, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05056051 (Additive Value of Wide-Area Transepithelial Sampling), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05056051 naunknown statusnot on this mapstarted 2020, after this paper: background citation

Additive Value of Wide-Area Transepithelial Sampling (WATS3D) in Detection of Recurrence of Intestinal Metaplasia Following Endoscopic Eradication Therapy (EET) for Barrett's Esophagus-Related Neoplasia

TypeinterventionalSponsorNorthwestern UniversityRan2020 to 2025Enrolled200ConditionsBarrett Esophagus, Esophageal CancerArmsWATS-3D tissue sampling prior to forceps biopsies, WATS-3D tissue sampling following forceps biopsies
3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Craig C ReedCenter for Esophageal Diseases and Swallowing, and Center for Gastrointestinal Biology and Disease, Division of Gastroenterology and Hepatology, Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, NC, USA.
Nicholas J ShaheenCenter for Esophageal Diseases and Swallowing, and Center for Gastrointestinal Biology and Disease, Division of Gastroenterology and Hepatology, Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, NC, USA. nshaheen@med.unc.edu.
University of North Carolina at Chapel Hill · US

Funding

DIGESTIVE DISEASES EPIDEMIOLOGY TRAINING PROGRAMT32DK007634 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI ROBERT S. SANDLER · 1990 to 2026
$7.4M
Non-Endoscopic Surveillance for Barrett's Esophagus Following Ablative TherapyK24DK100548 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI SHAHEEN, NICHOLAS J · 2013 to 2017
$896k
NIDDK NIH HHS K24 DK100548NIDDK NIH HHS T32 DK007634
6 · The paper itself

Abstract

Endoscopic ablative therapy including radiofrequency ablation (RFA) represents the preferred management strategy for dysplastic Barrett's esophagus (BE) and appears to diminish the risk of developing esophageal adenocarcinoma (EAC). Limited data describe the natural history of the post-ablation esophagus. Recent findings demonstrate that recurrent intestinal metaplasia (IM) following RFA is relatively frequent. However, dysplastic BE and EAC subsequent to the complete eradication of intestinal metaplasia (CEIM) are uncommon. Moreover, data suggest that the risk of recurrent disease is probably highest in the first year following CEIM. Recurrent IM and dysplasia are usually successfully eradicated with repeat RFA. Future studies may refine surveillance intervals and inform the length of time surveillance should be conducted following RFA with CEIM. Further data will also be necessary to understand the utility of chemopreventive strategies, including NSAIDs, in reducing the risk of recurrent disease.

Indexed as

Barrett EsophagusCatheter AblationDisease ProgressionEsophagusHumansPrecancerous ConditionsRecurrenceRisk AssessmentSecondary PreventionBarrett’s esophagusNatural historyRadiofrequency ablation

Identifiers

PMID29671157
OpenAlexW2801385148

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.